Clinical Trials Logo

Filter by:
NCT ID: NCT06162221 Recruiting - Clinical trials for Non-Small Cell Lung Cancer, NSCLC

Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC

Start date: January 18, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with each other. The first two subprotocols include the following: Subprotocol A: RMC-6291 + SOC Subprotocol B: RMC-6236 + SOC

NCT ID: NCT06162052 Recruiting - Burns Clinical Trials

Impact of a Telerehabilitation Program With Technology Enhancement on Post-burn Recovery

Start date: April 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effect of participating in a tele-rehabilitation program after a burn.

NCT ID: NCT06162039 Recruiting - Clinical trials for Acute Myocardial Infarction

Prevalence of Hemorrhagic Myocardial Infarction in the United States

MIRON-NATIONAL
Start date: December 13, 2023
Phase:
Study type: Observational

Registry analysis for prevalence of hemorrhagic myocardial infarction in the United States

NCT ID: NCT06162026 Recruiting - Clinical trials for Cognitive Impairment

Cognitive Screening Made Easy for PCPs - R33 Phase

Start date: February 2, 2024
Phase: N/A
Study type: Interventional

This project will facilitate early detection of cognitive decline in older adults through development and implementation of an automated risk assessment and cognitive screening tool for use in primary care. By providing an automated tool developed specifically to address the needs of PCPs, it will be easier to screen for cognitive impairment, increasing the number of older adults who are screened and thus identified and treated.

NCT ID: NCT06161974 Not yet recruiting - High Grade Glioma Clinical Trials

Study of Olutasidenib and Temozolomide in HGG

Start date: June 2024
Phase: Phase 2
Study type: Interventional

The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.

NCT ID: NCT06161831 Recruiting - Clinical trials for Human Papillomavirus Vaccination

HPV Vaccine Reminders - SEARCH II Study

Start date: April 22, 2024
Phase: N/A
Study type: Interventional

This RCT will take place at health centres and their affiliated schools and community immunization centers overseen by the Kampala Capital City Authority (KCCA) as well as at the Makerere/Mulago/Columbia Adolescent Health Clinic in Kampala. The investigators will assess the impact of vaccine text message and automated phone reminders on human papillomavirus (HPV) vaccination initiation and completion.

NCT ID: NCT06161688 Recruiting - Long COVID Clinical Trials

Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

PREVAIL-LC
Start date: April 9, 2024
Phase: Phase 2
Study type: Interventional

Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be susceptible to antiviral therapy that blocks viral replication, which has the potential to alleviate long COVID symptoms. This trial will study the safety and efficacy of Ensitrelvir (S-217622), an antiviral, to treat individuals with Long COVID in an adult population.

NCT ID: NCT06161675 Not yet recruiting - Clinical trials for Tobacco Use Cessation

Feasibility of Delivering VergeRx at FQHCs

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

Cigarette smoking in the U.S. is highest among low income and Medicaid insured adults, and unfortunately, low-income smokers are even less likely to attempt to quit, less likely to use evidence-based treatments, and thus less likely to be successful. Federally Qualified Health Centers (FQHCs), which generally provide healthcare services to low income and Medicaid insured patients, are more likely to serve individuals who use tobacco and are required to report tobacco use screening rates and their delivery of cessation interventions. Thus, FQHCs are an ideal community-partner to reach low-income smokers, particularly smokers who are not currently seeking treatment. To address this gap, the investigators developed a pharmacist-delivered smoking cessation intervention to help facilitate nicotine replacement therapy medication adherence among smokers. The proposed study aims to examine the feasibility of delivering the pharmacist-delivered smoking cessation intervention to FQHC patients who are ready to quit, and expanding the intervention for smokers not ready to quit by adding 2 pre-quit sessions focused on rate reduction. The investigators will also determine facilitators and barriers to adopting and implementing the program in FQHCs.

NCT ID: NCT06161597 Enrolling by invitation - Clinical trials for Families of Middle School Students at Title 1 Schools

Family Check-Up Online

FCO
Start date: October 25, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test the benefits of the Family Check-Up Online Program for parents of middle school students in Arizona. Participants will complete an online pre-survey, gain access to the online parenting program Family Check-Up, and have the option to meet with a coach to discuss the program. The participants will also complete a post-survey 3 months after enrollment.

NCT ID: NCT06161584 Recruiting - Geographic Atrophy Clinical Trials

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Start date: September 28, 2023
Phase:
Study type: Observational

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration